Conmed (CNMD) Tops Q1 EPS by 3c; Raises Outlook

Conmed (NASDAQ: CNMD) reported Q1 EPS of $0.57, $0.03 better than the analyst estimate of $0.54. Revenue for the quarter came in at $218.4 million versus the consensus estimate of $212.99 million.

GUIDANCE:

Conmed sees FY2019 EPS of $2.47-$2.52, from $2.42-$2.47 and the consensus of $2.45.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c